Synthesis and Radiolabeling of Glu-Urea-Lys with 99mTc-Tricarbonyl-Imidazole-Bathophenanthroline Disulfonate Chelation System and Biological Evaluation as Prostate-Specific Membrane Antigen Inhibitor.

Background: The Glu-Urea-Lys (EUK) pharmacophore as prostate-specific membrane antigen (PSMA)-targeted ligand was synthesized, radiolabeled with 99mTc-tricarbonyl-imidazole-BPS chelation system, and biological activities were evaluated. The strategy [2 + 1] ligand is applied for tricarbonyl labeling. (5-imidazole-1-yl)pentanoic acid as monodentate ligand and bathophenanthroline disulfonate (BPS) as a bidentate ligand formed a chelate system with 99mTc-tricarbonyl. EUK-pentanoic acid-imidazole and EUK were evaluated for PSMA active site using AutoDock 4 software. Materials and Methods: EUK-pentanoic acid-imidazole was synthesized in two steps. BPS was radiolabeled with 99mTc-tricarbonyl at 100°C for 30 min. The purified 99mTc(CO)3(H2O)BPS was used to radiolabel EUK-pentanoic acid-imidazole at 100°C, 30 min. Radiochemical purity, Log P, and stability studies were carried out within 24 h. Affinity of 99mTc(CO)3BPS-imidazole-EUK was performed in the saturation binding studies using LNCaP cells at 37°C for 1 h with a range of 0.001-1000 nM radiolabeled compound range. Internalization studies were performed in LNCaP cells with 1000 nM radiolabeled compound incubated for (0-2) h at 37°C. Biodistribution was studied in normal male Balb/c mice. The artificial intelligence predicts the uptake of radiolabeled compound in tumor. Results: The structures of synthesized compounds were confirmed by mass spectroscopy. Radiochemical purity, Log P, and protein binding were ≥95%, -0.2%, and 23%, respectively. The radiolabeled compound was stable in saline and human plasma within 24 h with radiochemical purity ≥90%. There was no release of 99mTc within 4 h in competition with histidine. The affinity was 82 ± 26.38 nM, and the activity increased inside the cells over time. Biodistribution studies showed radioactivity accumulation in kidneys less than 99mTc-HYNIC-PSMA. There was a moderate accumulation of radioactivity in the liver and intestine. Conclusion: Based on the results, 99mTc(CO)3BPS-imidazole-EUK can potentially be used as an imaging agent for studies at prostate bed and distal areas. The chelate system can be labeled with rhenium for imaging studies (fluorescent or scintigraphy) and therapy.

[1]  P. Geramifar,et al.  Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen. , 2020, Bioorganic chemistry.

[2]  Shaoli Song,et al.  Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer , 2020, Scientific Reports.

[3]  M. Gacitúa,et al.  Rhenium (I) Complexes as Probes for Prokaryotic and Fungal Cells by Fluorescence Microscopy: Do Ligands Matter? , 2019, Front. Chem..

[4]  D. Ye,et al.  The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients , 2018, Annals of Surgical Oncology.

[5]  U. Haberkorn,et al.  Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers , 2017, The Journal of Nuclear Medicine.

[6]  B. Ocampo-García,et al.  99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients. , 2017, Nuclear medicine and biology.

[7]  M. Luna-Gutiérrez,et al.  Clinical translation of a PSMA inhibitor for 99mTc-based SPECT. , 2017, Nuclear medicine and biology.

[8]  YingJian Zhang,et al.  99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. , 2017, Nuclear medicine and biology.

[9]  John Babich,et al.  Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection , 2017, The Journal of Nuclear Medicine.

[10]  M. Schwaiger,et al.  Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[11]  U. Haberkorn,et al.  The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[12]  U. Haberkorn,et al.  Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer , 2014, Pharmaceuticals.

[13]  J. Zubieta,et al.  Single amino acid chelate complexes of the M(CO)3 (+) core for correlating fluorescence and radioimaging studies (M = (99m) Tc or Re). , 2014, Journal of labelled compounds & radiopharmaceuticals.

[14]  W. Eckelman,et al.  99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer , 2013, The Journal of Nuclear Medicine.

[15]  J. Hsieh,et al.  A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen. , 2013, Molecular pharmaceutics.

[16]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[17]  C. Ferris,et al.  Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  H. Jadvar.  Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline , 2011, The Journal of Nuclear Medicine.

[19]  Martin G Pomper,et al.  68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. , 2010, Journal of medicinal chemistry.

[20]  W. Eckelman,et al.  Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide. , 2010, Bioconjugate chemistry.

[21]  Andrea F Armstrong,et al.  Evaluation of single amino acid chelate derivatives and regioselective radiolabelling of a cyclic peptide for the urokinase plasminogen activator receptor. , 2009, Nuclear Medicine and Biology.

[22]  Philip S Low,et al.  Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. , 2009, Molecular pharmaceutics.

[23]  M. Pomper,et al.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. , 2008, Journal of medicinal chemistry.

[24]  R. Schibli,et al.  Current use and future potential of organometallic radiopharmaceuticals , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  M. Pomper,et al.  11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). , 2002, Molecular imaging.

[26]  R. Schibli,et al.  Synthesis and properties of boranocarbonate: a convenient in situ CO source for the aqueous preparation of [(99m)Tc(OH(2))3(CO)3]+. , 2001, Journal of the American Chemical Society.

[27]  R. W. Parry,et al.  The preparation and properties of the boranocarbonates , 1967 .

[28]  M. Uder,et al.  99mTc‐MIP‐1404‐SPECT/CT for the detection of PSMA‐positive lesions in 225 patients with biochemical recurrence of prostate cancer , 2018, The Prostate.